Skip to main content
. 2015 Aug 13;2(10):1364–1376. doi: 10.1016/j.ebiom.2015.08.021

Fig. 1.

Fig. 1

Patients with hematological malignancies and healthy donors have different NK cell subset profiles. A) PBMCs from blood samples (bs) of a healthy donor and of a patient with multiple myeloma (MM) or from bone marrow (bms) of the patient with MM or samples of patients with other hematological diseases were stained for FACS analysis with anti-CD19 (B cells), − CD3 (T cells, CD3+CD56−) and − CD56 (NK cells, CD56+CD3−), to identify the different lymphocyte populations, and also with anti-CD16, to identify NK cell subsets at different stage of maturation, and with − CD45RA, and − CD45RO antibodies. Numbers in the quadrants indicate the percentage of cells. B) Percentage of different NK cell populations based on CD45RA and RO expression in healthy donors and in patients with hematological cancers. The populations correspond to the quadrants in A: upper left (CD45RA), bottom left (CD45RAdim), upper right (CD45RARO) and bottom right (CD45RAdimRO). The bars show the mean ± SD for each medical condition, Student t-test compare to healthy donor blood (left panel) or bone marrow (right panel) samples: *p < 0.01; **p < 0.001; ***p < 0.0001. HD, Healthy donor; MM, multiple myeloma; B-CLL, B-cell chronic lymphocytic leukemia; BCL, B-cell lymphoma; AML, acute myeloid leukemia; bs, blood samples; bms, bone marrow samples.